September 4, 2015: Vital Therapies is slashing 30 percent of its workforce and is cutting expenses in an effort to conserve capital after its late stage liver therapy failed.
September 4, 2015: In a move to expand its U.S. presence, Cipla struck a $550M deal to acquire two generic pharmaceutical companies, InvaGen Pharma, and Exelan Pharma, Cipla announced this morning.
September 4, 2015: Pfizer announced yesterday that it had closed its acquisition of Hospira. The acquisition had been announced on Feb. 5, totaling about $17B. The company projected about $800M in annual cost savings by 2018.
September 4, 2015: The FDA today announced that it had given breakthrough therapy designation to Genentech for its hemophilia A with factor VIII inhibitors drug, ACE910.